Mountain View, CA, United States of America

Mark Chen

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 18(Granted Patents)


Location History:

  • Mountain View, CA (US) (2015 - 2018)
  • San Mateo, CA (US) (2019)

Company Filing History:


Years Active: 2015-2019

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Mark Chen: Innovator in Antibody and Neurological Disorder Treatments

Introduction

Mark Chen is a prominent inventor based in Mountain View, CA. He has made significant contributions to the fields of biotechnology and neuroscience. With a total of 3 patents, his work focuses on innovative treatments for various medical conditions.

Latest Patents

Mark Chen's latest patents include groundbreaking inventions such as dual-specific anti-FGFR2 and FGFR3 antibodies. This invention provides compositions and methods for using these antibodies, which are crucial in targeting specific cancer pathways. Another notable patent involves the modulation of axon degeneration, which relates to the treatment of neurological disorders and nervous system injuries. This invention offers methods for using modulators of particular target proteins to influence the degeneration of neurons, particularly axons.

Career Highlights

Throughout his career, Mark Chen has worked with leading companies in the biotechnology sector, including Genentech, Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medical science.

Collaborations

Mark has collaborated with notable professionals in his field, including Ryan Jefferson Watts and Joseph Wesley Lewcock. These partnerships have further enhanced his research and development efforts.

Conclusion

Mark Chen's contributions to the fields of antibody development and neurological treatments highlight his role as a key innovator. His patents reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…